Although CCL5 was identified as a major contributor to the inflammatory response induced by plasma with atherosclerosis and, as such, it could be directly targeted, inhibition of CCL5 did not fully reverse the response in CD1c+ DCs (Fig. 5d,f). The gene discussed is CD1C; the disease is atherosclerosis.